These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9683844)

  • 1. Value of serial carcinoembryonic antigen levels in evaluating the response to chemotherapy in patients with advanced digestive cancers.
    Ychou M; Duffour J; Kramar A; Grenier J
    Oncol Rep; 1998; 5(5):1245-50. PubMed ID: 9683844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
    Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
    Kim G; Jung EJ; Ryu CG; Hwang DY
    Yonsei Med J; 2013 Jan; 54(1):116-22. PubMed ID: 23225807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
    Yamao T; Kai S; Kazami A; Koizumi K; Handa T; Takemoto N; Maruyama M
    Jpn J Clin Oncol; 1999 Nov; 29(11):550-5. PubMed ID: 10678558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA).
    Hanke B; Riedel C; Lampert S; Happich K; Martus P; Parsch H; Himmler B; Hohenberger W; Hahn EG; Wein A
    Ann Oncol; 2001 Feb; 12(2):221-6. PubMed ID: 11300328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.
    Byström P; Berglund A; Nygren P; Wernroth L; Johansson B; Larsson A; Einarsson R; Glimelius B
    Oncol Rep; 2010 Dec; 24(6):1645-52. PubMed ID: 21042763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
    Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
    Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
    Pectasides D; Mylonakis A; Kostopoulou M; Papadopoulou M; Triantafillis D; Varthalitis J; Dimitriades M; Athanassiou A
    Am J Clin Oncol; 1997 Aug; 20(4):348-53. PubMed ID: 9256887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
    Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
    Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy.
    An X; Ding PR; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH; Li YH
    Biomarkers; 2010 May; 15(3):243-8. PubMed ID: 20121626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of antitumor effect of chemotherapy for pancreatic cancer].
    Okada S
    Gan To Kagaku Ryoho; 1997 Nov; 24(14):2031-5. PubMed ID: 9388510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
    Hermunen K; Lantto E; Poussa T; Haglund C; Österlund P
    Acta Oncol; 2018 Jun; 57(6):750-758. PubMed ID: 29388498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
    Kaufman HL; Lenz HJ; Marshall J; Singh D; Garett C; Cripps C; Moore M; von Mehren M; Dalfen R; Heim WJ; Conry RM; Urba WJ; Benson AB; Yu M; Caterini J; Kim-Schulze S; Debenedette M; Salha D; Vogel T; Elias I; Berinstein NL
    Clin Cancer Res; 2008 Aug; 14(15):4843-9. PubMed ID: 18676757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?
    Trillet-Lenoir V; Chapuis F; Touzet S; Barbier JY; Freyer G; Gaudin JL; Lombard-Bohas C; Valette PJ; Lledo G; Gouttebel MC; Boyer JD; Chassignol L; Hamon H; Claudel-Bonvoisin S; Leprince E; Amoyal P; Glehen O; Darnand P; Heilmann MO; Bleuse JP
    Clin Oncol (R Coll Radiol); 2004 May; 16(3):196-203. PubMed ID: 15191007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.
    Sørensen NM; Byström P; Christensen IJ; Berglund A; Nielsen HJ; Brünner N; Glimelius B
    Clin Cancer Res; 2007 Jul; 13(14):4117-22. PubMed ID: 17634538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
    Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
    Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer.
    Grem JL; Steinberg SM; Chen AP; McAtee N; Cullen E; Hamilton JM; Allegra CJ
    Oncol Rep; 1998; 5(3):559-67. PubMed ID: 9538153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy.
    Al-Sarraf M; Baker L; Talley RW; Kithier K; Vaitkevicius VK
    Cancer; 1979 Oct; 44(4):1222-5. PubMed ID: 498010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes in tumor markers CEA, Ca 19-9 and Ca 125 in monitoring of response to chemotherapy in elderly patients with advanced gastric cancer].
    Caponetti R; Caponetti T; Vici P
    Clin Ter; 2002; 153(6):373-5. PubMed ID: 12645392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.